Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Pelthos Therapeutics Inc.AMEX: PTHS
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$75.03M, compared with -$23.44M a year earlier.
Context
- Retained earnings amounted to 51.6% of total assets at the end of Q1 FY2026, down 2521.2 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -220.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (64.79M) USD
- Year-over-year change
- -201.7%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (64.79M) | -201.7% |
| FY2024 | 2024-12-31 | (21.47M) | -58.8% |
| FY2023 | 2023-12-31 | (13.52M) | -120.2% |
| FY2022 | 2022-12-31 | (6.14M) | — |
Retained Earnings vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 retained earnings of -$75.03M is the 3rd highest of the 4 companies compared; the peer median is -$60M.
- Its year-over-year change of -220.1% is the lowest of 4, against a peer median of -13.7%.
- Retained earnings amounts to 51.6% of total assets for PTHS, versus a peer median of 459.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $1.11B | +972.0% | — | 47.6% | |
| Mar 2026 | -$60M | -13.7% | — | 552.2% | |
| Mar 2026 | -$75.03M | -220.1% | — | 51.6% | |
| Mar 2026 | -$141.69M | -26.2% | — | 459.1% | |
| Peer median (excluding PTHS) | -$60M | -13.7% | — | 459.1% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.